Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Trial
- Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines.Experimental and therapeutic medicine · 2026Article
- Pancreatic Cancer: Translating Tumor Biology into Actionability.Cancer discovery · 2026Review
- Article
- NAALADL1 modulates cellular resistance to Tumor Treating Fields in colorectal cancer.NPJ precision oncology · 2026Article
- Tumor treating field plus chemotherapy for locally advanced pancreatic adenocarcinoma: An international cost-effectiveness analysis.Scientific reports · 2026Article
- Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.International journal of molecular sciences · 2026Review
- Pancreatic cancer.Nature reviews. Disease primers · 2026Review
- Review
- Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate!Journal of gastrointestinal oncology · 2026Article
- Review
- Application of 200 kHz Tumor Treating Fields (TTFields) in Patients With Infratentorial High-Grade Glioma: Case Series.Brain tumor research and treatment · 2026Article
- The Preclinical Effects and Mechanisms of Biofield Therapy on Pancreatic Cancer Cell Growth and Metastasis.Cancer medicine · 2026Article
- Targeting ion channel dysregulation in tumors: emerging therapeutic opportunities.Trends in pharmacological sciences · 2026Review
- Induced Electric Fields Inhibit Breast Cancer Growth and Metastasis and Modulate the Immune Tumor Microenvironment.Breast cancer (Dove Medical Press) · 2026Article
- Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cells.Frontiers in oncology · 2026Article
- The electrical tumor microenvironment: abnormalities and opportunities.Frontiers in oncology · 2026Review
- Testing the effects of topical skin care products on Tumor Treating Fields (TTFields) adhesiveness of arrays and delivery of electric currents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
purposeTumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC).
methodsIn this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m
resultsOS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0]
conclusionThis study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.